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inclusion were Mehran Class I, II, or III lesions less than 30 mm in length, 50-99% diam- 
eter, covered in their entirety by no more than 2 contiguously placed stents inserted a 
minimum of 90 days prior to enrollment. After pre-dilation,15 mm NIRx TM Conformer Cor- 
onary Stent(s) with 1.0 Hg/mm2 (loaded drug/stent surface area) Paclitaxel in a slow- 
release formulation were implanted. Pre- and post- stent intra-vascular ultrasound 
(IVUS) was performed. The primary endpoint was the 30-day incidence of major cardiac 
events (MACE) defined as death, myocardial infarction, or target vessel revasculariza- 
tion. 
Results: The study has completed enrollment. All 29 patients had successful stent 
implantation. Fourteen patients received 2 stents; the rest received 1. Two peri-proce- 
dural MACE events have been reported at this time. Planned follow-up will be at 1,6, 12 
months and then annually. Repeat tVUS and angiography will be performed 6 months 
after the baseline procedure. 
Conclusions: Early feasibility data show promise for the use of polymer-controlled Pacli- 
taxel-eluting stents to treat ISR, Six month clinical and angiographic data will be reported 
in March 2002. 
1174-16 Sirolimus Coated Stent Versus Bare Stent: 
Angiographic and IVUS Analysis at Four-Month and 
One-Year Follow-Up 
Fausto Feres. Alexandre Abizaid, Gerardo Alvar(~z, Rodolfo Staico, Ibraim Pinto, Luiz A. 
Mattos, Ana C. Seixas, Luiz F. Tanajura, Aurea Chaves, Marinella Centemero, Andrea 
Abizaid, Robert Falotico, Judith Jaeger, Amanda Sousa, J. Eduardo Sousa, Institute 
Dante Pazzanese of Cardiology, SaG Pau/o, Brazil 
Background: Sirolimus (Rapamycin) coated stent has been shown to decrease intimal 
hyperplasia (IH) compared to bare stent. 
Objective: To assess the difference of IH between 4 and 12 months of sirolimus-coated 
compared to non-coated (bare) Bx Velocity coronary stents in patients with CAD. 
Methods: Forty-five patients underwent elective, single vessel stenting in our institution. 
Sirolimus-coated stents were implanted in 30 patients (15 fast [15 days] release formula- 
tion and 15 slow [28 days] release of sirolimus) and non-coated stents were implanted in 
15 pts. All stents were 18ram long and 3.0-3.5 mm in diameter. Angiographic and volu- 
metric IVUS analyses were performed by two experience analysts, after the procedure, 
at 4 and 12 month follow-up. 
Results: All stents were successfully deployed after balloon pre-dilatation and pts were 
discharged without complications. Baseline characteristics were similar between groups 
and 23% of the pts had diabetes. Reference vessel diameter was 2.96 _+ 0.3 mm (FR), 
2.98 +- 0.4 (SR) and 2.9_+ 0.4 mm (noncoated stent group], p=NS. 
FR4m FR12m SR 4m SR 12m Bare4m Bare12m 
Late loss (mm) 0.11_+0.11 0.2~0.3 0.05_+0.1 0.08+0.3 0.84+-0.37 0.91:LO.4 
Intimal hyperplasia (mm3) 2.04+_3.8 2.5_+4.3 0.23+-0.89 0.3_+1.3 9.01+~21.5 42.3_+23.5 
FR vs SR: p = NS; FR vs Bare: p< 0.0001; SR vs Bare: p < 0.0001 ; 4 m vs 12 m: p = NS 
Conclusion: Late lumen loss and intimal hyperplasia was virtually absent after implanta- 
tion of sirolimus-coated stents and significantly less than non-coated stents, regardless 
the formulation used (FR versus SR) and the time of follow-up (4 versus 12 months). 
1174-17 Ef fect  on Restenosis With a Pecl i taxel  Eluting Stent: 
Factors Associated With Inh ib i t ion  in the Elutes Cl inical  
Study 
Bernard Chevalier. Ivan De Scheerder, Anthony Gershlick, Edouardo Camezind, Antoine 
Gommeaux, Christian Vrints, Nicholas Reifart, Luc Missault, Jean-Jacques Goy, Alan 
Heldman, Jeffrey Brinker, Albert E. Raizner, The ELUTES Study group, Centre 
Cardio/ogique du Nord, Saint-Denis, France. 
Background: In-stent restenosis remains a clinical problem and the efficacy of drug- 
coated stents is unproven. Paclitaxel inhibits microtubule formation rendering cells cyto- 
static and has been shown to inhibit restenosis in animal models. 
Methods: To evaluate the safety and efficacy of the paclitaxel-eluting V-Flex Plus TM coro- 
nary stent (without polymer coating), a multicenter, randomized, triple-blinded, dose- 
ranging study (ELUTES) with 4 progressive dose treatment groups and one control 
group (uncoated stent) was conducted. In-hospital and 6 month clinical and angiographic 
data were collected. Patients with severe calcification, left main lesion and multiple 
lesions in the target vessel were excluded. Study endpoints were percent diameter 
stenosis and late loss at 6 months measured by QCA, and MACE at I and 6 months. The 
study had independent core lab QCA analysis, clinical events adjudication, and data 
safety monitoring. 
Results: 190 pts received stents (37% LAD, 37% RCA, 21% LCX, 5% RAM). Patients 
were 81% male. Mean age was 60 years. Patients had 56% one- and 27% two-vessel 
disease, 11% unstable angina, 34% prior MI, 2% prior CABG. Lesions were 27% A, 63% 
B1, and 9% B2. There was 1 death, no Q Wave Ml's, no emergent CABG, one re-PTCA 
(0.5%) and 5 (2.6%) non Q ML MACE rate at 30 days was 1.1%. Procedural QCA on 183 
patients and follow-up QCA on 110 patients revealed a reference vessel diameter of 2.96 
+- 0.41mm, a minimum lumen diameter of 0.55 -+ 0.27mm prestent, 2.68 + 0.39 mm post 
stent, and 2.16 _+ 0.78 mm at 6 months. Overall residual stenosis at follow-up was 27.1 +4- 
24.5% and late loss was 0.49 ±0.68 mm including the control group and the four progres- 
sively active groups. Follow-up will be completed in November 2001 after which unblind- 
ing and analysis of clinical, angiographic and procedural factors associated with 
restenosis inhibition will be completed. 
Conclusions: Even without unblinding, a paclitaxel-coated coronary stent with no poly- 
mer appears to be associated with reasonable short-term safety and seems compatible 
with mid-term restenosis inhibition. Unblinding will permit further description of factors 
associated with efficacy at the time of the presentation. 
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1174-18 Are Sirolimus-Eluting Stents Inducing Vascular 
Remodeling? A Subgroup Analysis of 3D-Intrevascular 
Ultrasound in the RAVEL Trial 
Muzaffer Deoertekin, K. Tanabe, E. Regar, J. E. Souse, A, Colombo, G. Guagliumi, J. L. 
Guermonperez, M. C. Morice, P. W. Serruys, Thoraxcenter, Rotterdam, The Netherlands. 
Background: Abolition of intra-stent neointimal hyperplasia after Sirelimus-eluting stent 
(SES) implantation has been demonstrated in a pilot study (FIM: First In Men) and con- 
firmed in the double-blind, randomized, controlled RAVEL tdal. However, the influence of 
SES on plaque burden behind the struts and on the vessel wall (expansion or retraction 
of the external elastic membrane area; EEM) has not been documented. Aim: To com- 
pare vessel remodeling at 6-month follow-up (FU) after SES and uncoated stent (US) 
implantation in a subset of patients randomized in the RAVEL trial at 6 of 19 participating 
centers. Methods: Patients with single de-novo lesions were randomized to receive 
either an 18 mm SES Bx-VELOCITY tm stent (Cordis) or an US Bx-VELOCITY tm stent. 
Motorized IVUS pullback (0.5 mm/sec) was performed at 6-month FU and analyzed by 
an independent core lab (Cardialysis, Rotterdam, NL). Total vessel volume (TVV), stent 
volume (SV), and lumen volume (LV) were measured. Total plaque volume (TPV), plaque 
volume behind the stent (PBS) and neointimal hyperplasia (NIH) were calculated as 
"TVV-LV", "TVV-SV"; "SV-LV", respectively. Data were compared using an unpaired t- 
test, Results: 
Volume (mm 3) SES (n=36) US (n=27) p-value 
TVV 275.7+ 69.1 283.7+71.9 ns 
SV 127.7+- 30.7 138.1 + 36.1 ns 
LV 125.5+_ 32 96.9+ 40.6 0,003 
TPV 150.2+_ 44.4 186.8:1:52.8 0.004 
PBS 148.0+- 45.5 145.6:1:0.41 ns 
NIH 2.18 + 7.2 41.2 + 32,3 O.O00 
Conclusion: PBS and TVV had similar volumes at FU suggesting that no significant 
plaque shrinking or positive/negative remodeling occurred as result of Sirolimus elution. 
in other words, SES is effective in preventing NIH without influencing the vessel wall 
structure when compared with US. 
1174-1 9 SCORE Six-Month Angiogrephic Results: Improved 
Restenosis in Patients Receiving the QUADDS-QP2 
Drug-EluUng Stent Compared With the Control, Bare 
Stents  
Eberhard Grube, Alexandra J. Lanskv. Nicholas Reifarf, Jean Fajadet, Germano 
DiSciascio, Carlo DiMado, Karl Hauptmann, Antonio Colombo, Roland Bach, Sigmund 
Silber, for the SCORE tnvsstigators, Cardiovascular Research Foundation, New York, 
New York, Lenox Hi//Heart and Vascular Institute, New York, New York. 
Background: The QUADDS-QP2 stent is a 316L stainless steel stent that delivers 4000 
ug QP2 (an antiproliferative taxane derivative) from high capacity polymer sleeves. The 
SCORE trial was stopped early due to higher thrombosis with the QP2 Stent after ran- 
domizing 267 of 400 pts with de novo native lesions to a bare metal control stent or the 
QP2 Stsnt (available sizes: 3.0 or 3.5mm; 13 or 17 mm long). Methods: We report the 
quantitative angiographic (QCA) results of the first 260 pts enrolled, with follow-up avail- 
able in 77% (N=202). Restenosis rates (RS) include thrombosis cases (9.4% QP2 vs 0% 
Quest). Results: The stent was deployed successfully in all cases. Lesion characteristics 
were similar at baseline with ACC/AHA class >B1 in 30.9% QP2 vs 33.6% bare stent, 
p=NS (see table). FoUow-up restenosis was reduced by 57%. Conclusion: Despite the 
safety concerns of high dose QP2 delivered via a high capacity polymer on the QUEST 
stent, striking reductions in RS are observed within the targeted stent zone, which 
remains overestimated due to the inclusion of thrombosis cases. Complete adjudicated 6 
month data will be presented. 
QUADDS-QP2 QUEST p value 
N=134 N=126 
Reference, mm 2.92±0.43 3.00±0.48 0.163 
Lesion length, mm 11.67±4.62 11.96±4.36 0.603 
Final MLD, mm 2.28±0.46 2.28±0.53 0.988 
Follow-up Stent MLD, mm 2.31±0.71 1.75±0.79 <0.001 
Stent Late Loss, mm 0.35±0.73 0.65±0.71 0.004 
Restenosls Stent % 10.1% 36.9% <0.001 
1174-20 Treatment of In-Stent Restenosis Using Paclitaxel 
Eluting Stents: Results From the Leuven Pilot Trial 
Ivan De Scheerder, Yanming Huang, Joseph Dens, Lan Wang, xiaoshun Liu, Walter 
Desmet, University Hospitals Leuven, Leuven, Belgium. 
Coronary stents are still hampered by an increased neointimal hyperplasia caused by 
vessel injury due to stent inplantation and due to a foreign body response induced by the 
stent itself. 
Paclitaxsl, extracted from the Pacific Yew Tree, Taxus grevifolia, possess potent immun- 
osuppressive effects, inhibiting cellular activities such as mitosis, migration, endocytosis 
and secretion. 
Pre-clinical investigation with the Cook Paclitaxel-coated coronary stent showed a slow 
in-vivo release of the drug. Fourteen days after stent inplantation in a pig coronary artery, 
69% of the drug was locally released. This resulted in a significant decrease of late loss, 
o 
~3 
=5 
2 
o 
5 
Pq 
rN 
(,3 
60A ABSTRACTS - ACCIS2002 (Angiography & Interventional Cardiology) JACC March 6, 2002 
compared with a non-coated bare stent, one month after inplantation. 
In this pilot tdal, 21 patients (mean age:62+/-9 years) with a recurrent in-stent restenosis 
were treated with a single 60pg paclitaxel coated stent. Fourteen pts were males, 6 dia- 
betic, and 13 were treated for hypercholesteroJemia. All inplants were sucoessfulL All 
patients recieved Ticlopidine (250mg) during 3months.There were no major in-hospital 
complications. At follow-up two pts experienced a subacuta thrombotic occlusion of the 
stentad artery. One after 14 days under ticlopidine treatment and one after 4m when the 
ticlopidine treatment was already stopped for 3 weeks. Three patients underwent an 
early control coronarography because of recurrence of symptoms. One showed an in- 
stent rastenosis in the paclitaxel coated stent. All remaining patients underwent a control 
ooronarogram at 6 months follow-up. Two additional patients showed a significant in- 
stant restenosis. 
Conclusion: Paclitaxel eluting stents to treat in-stant restenosis is a promissing new treat- 
ment modality. Late trombotio stant occlusion due to retarded endothelial cell regrewth is 
however a concern and prolonged antiplatelet reatment seems to be mandatory. 
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1175-1 Mechanisms of Lumen Narrowing of Saphenous Vein 
Bypass Grafts 12 Months After Implantation: An 
Intravascular Ultrasound Study 
Hideaki Kaneda, Mitsuyasu Terashima, Takefumi Takahashi, Stein Iversen, Thomas 
Felderhoff, Eberhard Grube, Paul G. Yock, Peter J. Fitzgerald, Yasuhiro Honda, Stanford 
Universi~ Stanford, California, Heart Center Siegburg, Siegburg, Germany. 
Background: Diseased saphenous vein bypass grafts (SVG) several years after surgery 
have been shown to undergo vascular remodeling similar to native coronary arteries. 
However, little in vivo data exist as to the early morphologic changes of SVG. The aim of 
this study was to examine whether the remodeling process occurs in SVG in the early 
phase. 
Methods: We studied 30 SVG by IVUS using automated pullback 12 months after 
implantation. In all cases, IVUS images were analyzed between 10 and 60 mm from the 
proximal anastomosis. Lumen (LA), intima (IA), and vessel areas (VA, defined as the 
area within the outer border of a hypoechoic intima[ layer) were computed. Quantitative 
analysis was performed at 3 cross-sections: the minimum lumen area (MLA) site with the 
smallest lumen area, and the proximal and distal reference sites with the least intimal 
burden within 10 mm from the MLA site. Area changes (4) were calculated as the MLA 
site minus the average of the reference sites. 
Results: In this cohort, 70% of the MLA sites had a smaller VA than the references, indi- 
cating inadequate compensatory remodeling in the majority of SVG. Overall, VA at the 
MLA sites was significantly smaller than the references (9.7+~.9 vs 11.C~_3.2 mm 2, 
p<0.0001), despite the smaller LA (7.2±2.6 vs 9.5~2.9 mm 2, p<0.0001) with a larger IA 
(2.5±2.1 vs 1.2±1.3 mm 2, p<0.0001) at the MLA site. The relative contributions of AVA (- 
1.0±1.4 mm 2) and ~IA (1.3±1.3 mm 2) to lumen compromise (-2.3±1.4 mm 2) were 43% 
and 57%, respectively. On the other hand, simple linear regression analysis revealed a 
significant positive correlation between AIA and AVA (y=-1.7+0.52x, r=0.50, p=0.005). 
Conclusions: The mechanism of early lumen compromise in SVG may be a combina- 
tion of entire vessel narrowing and intimal hyperplesia. However, positive remodeling 
process appeared to remain to compensate for excessive intimal proliferation. These 
findings may be important to incorporate when evaluating biological techniques for 
improving long-term graft patency. 
11 75-2 Determinants of Carotid Artery Size: An Intravascular 
Ultrasound Analysis 
Georae K. Daniel. Nell J. Weissman, Gary S. Mintz, Daniel A. Canos, Dancia Langley, 
Lowell F. Satler, John R. Laird, Washington Hospita/Center, Washington, Dist. of 
Co/umbia. 
Background: During carotid interventions, a wide range of carotid size is noted. Coro- 
nary luminal dimensions are dependent on body size, gender and the presence of diffuse 
disease however; the determinants of carotid size are unknown. Methods: We evaluated 
carotid artery size using intravascular ultrasound (IVUS) in 83 pts (55 men) prior to 
carotid intervention. External elastic membrane (EEM) and luminal cross sectional area 
(CSA) were measured at a non-stenotic common carotid artery (CCA) segment. Body 
size (BSA=body surface area) and other demographic information were systematically 
collected. Univariant and multivadant analysis was performed. Results: Patient age, 
hypertension, diabetes, hypercholestarolemia and tobacco use were not related to 
carotid size. Men had larger CCA EEM and lumens compared to women (p = .001). On 
univariant analysis, CCA size was also strongly related to body size (p = < .0001 ). 
Male Female p value 
EEM-CSA (mm 2) 67±14 56±13 0.001 
Lumen-CBA (mm 2) 39±10 32_+11 0.008 
EEM-CSA/BSA (rem 2) 34_+7 33±7 0.363 
Lumen-CSA/BSA (mm 2) 20±5 19_+7 0.502 
However, on multivariant analysis BSA was the only independent predictor of carotid 
size. Conclusion: Although carotid arteries are larger in men and are proportionate to 
body size, body size is the primary determinant of both carotid EEM and lumen size. 
1175-21 Gold-Coated Versus Uncoated Stents: An Intravascular 
Ultrasound Volumetric Analysis Showing an Increase in 
InUmal Hyperp las ia  in Gold-Coated Stents  
Andrea S. Abizaid, Alexandre Abizaid, Igor Mattos, Gary S. Mintz, Rodolfo Staico, Marco 
Costa, Ana C. Seixas, J. Eduardo de Paula, Aurea Chaves, Madnella Centemero, Luiz E 
Tanajura, Roxana Mehran, Amanda Sousa. J. Eduardo Sousa, Institute Dante 
Pazzanese of Cardiology, Sad Pau/o, Brazi/, Lenox Hi//Heart and Vascular Institute, 
Cardiovascu/ar Research Foundation, New York, New York. 
Background: Gold-coated (GC) stents enhance radiopacity which is extremely useful 
when precise stant placement is required. However, GC stents may cause reactive 
neointimal hyperplasia due to stent surface alterations. Previous studies have shown 
trend toward higher clinical and angiographic recurrence after GC stenting compared to 
stainless-steel (SS) stants. Methods: We randomized 48 patients with coronary artery 
disease to receive either a GC NIROYAL stent (n=24) or SS NIR PRIMO stent (n=24). All 
patients had angiography and intravascular ultrasound (IVUS) follow-up at six months 
Results: Baseline and angiographic characteristics were similar between the two 
groups. At 30 days, there was no sub-acute thrombosis in either group. Six-month IVUS 
results are shown in the table. At 6-months, target lesion revascularization was 26.1% in 
the GC group vs. 13.6% in the SS group (p=0.45). 
GC Stent SS stant p 
Conclusions: GC stants are associated with more neointimal hyperplasia by volumetric 
IVUS analysis at 6-months compared to SS stents, resulting in a trend toward higher clin- 
ical recurrence. Larger randomized trials are needed to demonstrate any equivalence 
between GC and SS stents. 
1175-22 Improvement  of  Microvascular Function in Chronic 
Coronary Occlusions Within Six Months After 
Recanalization: Influence of Diabetes and Hypertension 
Gerald S. Wemer. Markus Ferrari, Oliver Gastmann, Barbara M. Richartz, Hans R. 
Figulla, Klinik /nnere Medizin I//, Jeca, Germany. 
Micrevascular dysfunction (MD) after PTCA may cause a reduced coronary flow velocity 
reserve (CFVR) even after optimum treatment of the epicardial lesion. The present study 
evaluated the prevalence of MD in total chronic coronary occlusions (TCO), and a poten- 
tial recovery dudng followup. 
In 64 patients with successful recanalization and stenting of a TCO (minimum duration 1 
months; mean 5 months) a Doppler wire was used to assess CFVR after stent placement 
by measuring average peak velocity (APV) during hyperemia induced by i.c. 30 g ade- 
nosine, in addition the fractional flow reserved (FFR) was measured by an i.c. pressure 
wire. Patients were reexamined after 5.5±1.4 months. CFVR was obtained in 54 pts; 10 
pts were not reevaluated because of a raocclusion; in 19 pts with restenosis CFVR was 
obtained after repeat PTCA. MD was defined by CFVR<2.0 and FFR 0.75. 
CFVR after PTCA was 1.94±0.64. It was <2.0 in 56%, whereas FFR<0.75 was observed 
in only 8%, indicating MD in 48%. At followup CFVR increased to 2.28±0.82 (p=0.002) 
with a decrease of basal APV from 29±15 to 24±15 cm/s (p<0.05) and no change of max- 
imum hyperemic APV. At followup MD was observed in only 23%. The ejection fraction 
had improved from 53±20 to 60±18% (p<0.001), and the regional dysfunction was like- 
wise improved. CFVR after PTCA improved both in patients with normal regional function 
as well as with severely impaired regional function. CFVR improved also in patients with 
restenosis and repeat PTCA. 73% of patients had either diabetes and/or hypertension. 
They had a lower CFVR after PTCA as compared with those without eomorbidity 
(1.83±0.68 vs 2.17±0.44; p<0.05). The CFVR at followup was 2.18±0.79 and 2.55±0.84, 
respectively. The difference in CFVR, and of MD, was still observed in patients with dia- 
betes and/or hypertension (ANOVA p=0.067). 
Microvascular dysfunction is observed in 50% of patients with TCO. During 6 months fol- 
Iowup CFVR improved significantly as indicator of a restored MD. The improvement 
occurred independent of regional dysfunction and the incidence of restenosis. However, 
MD appeared to improve less and remained impaired in patents with diabetes and/or 
hypertension. 
IVUS @ 6-months 
Stant volume, mm 3 134.7 ± 62.5 148.1 ± 94.7 0.66 
Mean stent area, mm 2 7.5±1.8 8.0~3.3 0.58 
Lumen volume, mm 3 87.2 ± 44.9 102.0 + 75.8 0.30 
Mean lumen area, mm 2 4.2+1.7 5.6_+3.2 0.18 
Intimal hyperplasia volume, mm 3 57.9 ± 29.9 45.8 ± 30.6 0.30 
Mean Intimal hyperplasla ares, mm 2 3.6±1.5 2.4_+1.0 0.02 
In-stent obstruction, % 45.2 _+ 18.9 32.8 _+ 13.8 0.05 
